SCHEMBL6316367

SCHEMBL6316367

COc1ccc(CNC(=O)c2c(-c3ccc(C)s3)noc2N)cc1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.52
ALDH1A1 P00352 4/20 0.52
L3MBTL1 Q9Y468 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.48
MEN1 O00255 1/20 0.48
LMNA P02545 1/20 0.48
ESR1 P03372 1/20 0.48
KMT2A Q03164 1/20 0.48
TSHR P16473 1/20 0.47
HPGD P15428 2/20 0.47
CHRM4 P08173 3/20 0.47
TP53 P04637 1/20 0.47
MDM2 Q00987 1/20 0.47
RAB9A P51151 1/20 0.47
ATM Q13315 1/20 0.47
FLT1 P17948 1/20 0.46
LRRK2 Q5S007 1/20 0.46
POLB P06746 2/20 0.46
RXFP1 Q9HBX9 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6323626 0.90 TP53 (0.53) MAPTALDH1A1L3MBTL1SMN1; SMN2MEN1
SCHEMBL6314681 0.90 MAPT (0.52) MAPTALDH1A1L3MBTL1SMN1; SMN2MEN1
SCHEMBL6317131 0.90 MAPT (0.48) MAPTALDH1A1L3MBTL1SMN1; SMN2MEN1
SCHEMBL6320945 0.89 KMT2A (0.49) MAPTALDH1A1SMN1; SMN2MEN1LMNA
SCHEMBL6315045 0.88 ADRB2 (0.47) MAPTALDH1A1SMN1; SMN2HPGDFLT1
SCHEMBL6317603 0.87 GAA (0.53) MAPTALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL6317710 0.87 KMT2A (0.47) MAPTALDH1A1L3MBTL1SMN1; SMN2MEN1
SCHEMBL6316883 0.85 TSHR (0.48) MAPTALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL6318905 0.82 CHRM4 (0.45) LMNAKMT2ACHRM4ATM
SCHEMBL6322727 0.82 ALDH1A1 (0.50) MAPTALDH1A1L3MBTL1SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 MAPT 281/4885ALDH1A1 4444/4885L3MBTL1 4176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.